118,057 Shares in Epizyme, Inc. (EPZM) Purchased by OxFORD Asset Management LLP

OxFORD Asset Management LLP purchased a new position in Epizyme, Inc. (NASDAQ:EPZM) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 118,057 shares of the biopharmaceutical company’s stock, valued at approximately $1,783,000. OxFORD Asset Management LLP owned about 0.20% of Epizyme at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of EPZM. Palo Alto Investors LLC increased its holdings in shares of Epizyme by 57.8% in the 1st quarter. Palo Alto Investors LLC now owns 4,791,051 shares of the biopharmaceutical company’s stock worth $82,167,000 after buying an additional 1,755,255 shares during the last quarter. Oracle Investment Management Inc. bought a new position in shares of Epizyme in the 1st quarter worth $8,866,000. Vanguard Group Inc. increased its holdings in shares of Epizyme by 6.2% in the 2nd quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock worth $51,640,000 after buying an additional 200,982 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Epizyme in the 1st quarter worth $1,975,000. Finally, Iguana Healthcare Management LLC bought a new position in shares of Epizyme in the 1st quarter worth $1,286,000. 72.23% of the stock is currently owned by hedge funds and other institutional investors.

Epizyme, Inc. (EPZM) opened at 18.55 on Monday. Epizyme, Inc. has a 12-month low of $8.38 and a 12-month high of $20.45. The company’s market cap is $1.08 billion. The company’s 50 day moving average is $17.39 and its 200 day moving average is $15.45.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.08. The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.95 million. During the same quarter in the prior year, the firm posted ($0.49) EPS. The company’s revenue for the quarter was up 2027.7% on a year-over-year basis. Analysts forecast that Epizyme, Inc. will post ($2.36) earnings per share for the current fiscal year.

A number of equities analysts have recently commented on EPZM shares. Royal Bank Of Canada set a $20.00 price target on shares of Epizyme and gave the stock a “buy” rating in a report on Monday, June 12th. Oppenheimer Holdings, Inc. set a $26.00 price target on shares of Epizyme and gave the stock a “buy” rating in a report on Wednesday, June 14th. Citigroup Inc. increased their price target on shares of Epizyme from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, June 16th. Leerink Swann reissued an “outperform” rating and issued a $31.00 price target on shares of Epizyme in a report on Friday, June 16th. Finally, Cann reissued a “buy” rating and issued a $26.00 price target on shares of Epizyme in a report on Wednesday, June 21st. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $23.33.

WARNING: This story was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://ledgergazette.com/2017/10/09/118057-shares-in-epizyme-inc-epzm-purchased-by-oxford-asset-management-llp.html.

In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $15.68, for a total value of $235,200.00. Following the sale, the insider now owns 22,228 shares in the company, valued at $348,535.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David M. Mott purchased 200,000 shares of Epizyme stock in a transaction that occurred on Monday, September 18th. The stock was acquired at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $91,500. The disclosure for this purchase can be found here. In

Several other large investors also recently modified their holdings of EPZM. Palo Alto Investors LLC increased its holdings in shares of Epizyme by 57.8% in the 1st quarter. Palo Alto Investors LLC now owns 4,791,051 shares of the biopharmaceutical company’s stock worth $82,167,000 after buying an additional 1,755,255 shares during the last quarter. Oracle Investment Management Inc. bought a new position in shares of Epizyme in the 1st quarter worth $8,866,000. Vanguard Group Inc. increased its holdings in shares of Epizyme by 6.2% in the 2nd quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock worth $51,640,000 after buying an additional 200,982 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Epizyme in the 1st quarter worth $1,975,000. Finally, Iguana Healthcare Management LLC bought a new position in shares of Epizyme in the 1st quarter worth $1,286,000. 72.23% of the stock is currently owned by hedge funds and other institutional investors.

Epizyme, Inc. (EPZM) opened at 18.55 on Monday. Epizyme, Inc. has a 12-month low of $8.38 and a 12-month high of $20.45. The company’s market cap is $1.08 billion. The company’s 50 day moving average is $17.39 and its 200 day moving average is $15.45.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.08. The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.95 million. During the same quarter in the prior year, the firm posted ($0.49) EPS. The company’s revenue for the quarter was up 2027.7% on a year-over-year basis. Analysts forecast that Epizyme, Inc. will post ($2.36) earnings per share for the current fiscal year.

A number of equities analysts have recently commented on EPZM shares. Royal Bank Of Canada set a $20.00 price target on shares of Epizyme and gave the stock a “buy” rating in a report on Monday, June 12th. Oppenheimer Holdings, Inc. set a $26.00 price target on shares of Epizyme and gave the stock a “buy” rating in a report on Wednesday, June 14th. Citigroup Inc. increased their price target on shares of Epizyme from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, June 16th. Leerink Swann reissued an “outperform” rating and issued a $31.00 price target on shares of Epizyme in a report on Friday, June 16th. Finally, Cann reissued a “buy” rating and issued a $26.00 price target on shares of Epizyme in a report on Wednesday, June 21st. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $23.33.

WARNING: This story was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://ledgergazette.com/2017/10/09/118057-shares-in-epizyme-inc-epzm-purchased-by-oxford-asset-management-llp.html.

In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $15.68, for a total value of $235,200.00. Following the sale, the insider now owns 22,228 shares in the company, valued at $348,535.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David M. Mott purchased 200,000 shares of Epizyme stock in a transaction that occurred on Monday, September 18th. The stock was acquired at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $91,500. The disclosure for this purchase can be found here. Insiders sold 45,000 shares of company stock worth $688,950 in the last 90 days. 25.20% of the stock is currently owned by company insiders.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply